Manifest Technologies, developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company.

The financing round included investments by Kaleida Capital, Atma Capital, Connecticut Innovations and angel investors.

Manifest Technologies is transforming CNS health through AI-powered precision neuroscience and computational neuroimaging. Manifest was founded in 2021 by a group of leading scientists who have created the NAIO™ (Neuroscience and Artificial Intelligence Optimized) platform. NAIO™ incorporates proprietary software and several patents under an exclusive license from Yale University. Manifest is building a suite of specific applications out of the NAIO™ platform to meet the needs of both pharmaceutical CNS R&D and health care providers.